Want to see BLRX full AI Analyst Report?
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-9.42% Downside)
Action:Reiterated
Date:09/06/26
BLRX scores low primarily due to very weak financial performance (deep losses, shrinking revenue, and ongoing cash burn), reinforced by a technically weak price trend below key moving averages. The earnings call provides a meaningful but limited offset via positive clinical execution and stated runway into 1H 2027, while valuation remains constrained by ongoing losses and no dividend support.
Positive Factors
GLIX1 clinical progress
Rapid enrollment and reported early safety and tolerability reduce execution risk for GLIX1’s development program. Progress across multiple clinical sites supports timely Phase I data and could create a foundation for broader oncology development if the asset continues to validate clinically.
Negative Factors
Deep and persistent losses
Operating expenses currently overwhelm gross profit, leaving the company deeply loss-making despite a roughly 70% gross margin. Continued negative earnings weaken internal funding capacity and make successful clinical or commercial execution increasingly important to long-term financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
GLIX1 clinical progress
Rapid enrollment and reported early safety and tolerability reduce execution risk for GLIX1’s development program. Progress across multiple clinical sites supports timely Phase I data and could create a foundation for broader oncology development if the asset continues to validate clinically.
Read all positive factors
Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.49M
Dividend YieldN/A
Average Volume (3M)19.99K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth-91.94%
EPS Growth55.29%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.82
Shares Outstanding4,848,991
10 Day Avg. Volume43,804
30 Day Avg. Volume19,990
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.00Price Target Upside842.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)$1.95M
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company Description
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successful...
How the Company Makes Money
BiolineRx primarily makes money through (1) product-related revenue from the commercialization of APHEXDA (motixafortide) in the United States and (2) collaboration-related payments tied to partnerships.
1) Product revenue (APHEXDA): The company ...
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date:Aug 31, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.Positive Updates
GLIX1 Clinical Trial Progress
BioLineRx initiated the Phase I/IIa GLIX1 trial in March, dosed the first patient in April at NYU Langone Health, and has since enrolled patients at Northwestern University and Moffitt Cancer Center. Recruitment is progressing extremely well and according to plan; dosing has begun in the second of five planned Phase I cohorts, with the third cohort expected to commence dosing in September. The company reported that GLIX1 has shown very good safety and tolerability a little more than four months into the study and continues to anticipate Phase I data in the first half of 2027.
Negative Updates
Quarterly Net Loss Increased
Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million or approximately 10.3%.
Read all updates
Q2-2026 Updates
Positive
Negative
GLIX1 Clinical Trial Progress
BioLineRx initiated the Phase I/IIa GLIX1 trial in March, dosed the first patient in April at NYU Langone Health, and has since enrolled patients at Northwestern University and Moffitt Cancer Center. Recruitment is progressing extremely well and according to plan; dosing has begun in the second of five planned Phase I cohorts, with the third cohort expected to commence dosing in September. The company reported that GLIX1 has shown very good safety and tolerability a little more than four months into the study and continues to anticipate Phase I data in the first half of 2027.
Read all positive updates
Company Guidance
BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40M | 1.19M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 976.26K | 430.39K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -8.26M | -224.77K | 3.92M | -57.09M | -22.14M | -25.37M |
| Net Income | -8.03M | -1.18M | -9.22M | -60.61M | -24.95M | -27.05M |
Balance Sheet | ||||||
| Total Assets | 33.48M | 40.90M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 7.94M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 16.86M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 13.77M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -10.90M | -8.16M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -10.88M | -8.14M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 12.45M | -8.61M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -4.51M | 8.95M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Negative
2.76
Price Trends
2.84
Negative
2.93
Negative
2.89
Negative
Market Momentum
-0.06
Positive
40.78
Neutral
12.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 2.76 is above the 20-day moving average (MA) of 2.74, below the 50-day MA of 2.84, and below the 200-day MA of 2.89, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.78 is Neutral, neither overbought nor oversold. The STOCH value of 12.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $16.49M | -0.28 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $13.49M | -1.39 | -47.22% | ― | -91.94% | 55.29% | |
45 Neutral | $11.72M | -0.06 | 204.18% | ― | ― | 35.03% | |
42 Neutral | $14.02M | -0.91 | -748.08% | ― | ― | ― | |
42 Neutral | $9.45M | -0.06 | -443.08% | ― | ― | 75.09% | |
40 Underperform | $10.40M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
BLRX
Bioline RX Ltd Sponsored ADR
2.55
-1.69
-39.86%
DARE
Daré Bioscience
0.72
-1.41
-66.38%
GTBP
GT Biopharma
5.98
-14.02
-70.10%
KALA
KALA BIO
0.56
-762.94
-99.93%
CTXR
Citius Pharmaceuticals
0.58
-0.63
-51.90%
AEON
AEON Biopharma
0.23
-0.51
-68.78%
Bioline RX Ltd Sponsored ADR Corporate Events
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal
Aug 31, 2026
On August 27, 2026, BioLineRx entered into a securities purchase agreement for a registered direct offering of 480,696 ADSs and pre-funded warrants for up to 868,225 ADSs, alongside a concurrent private placement of unregistered warrants for up to...
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results
Aug 31, 2026
BioLineRx reported unaudited financial results for the quarter ended June 30, 2026, on August 31, 2026, highlighting a net loss of $4.3 million on revenues of $0.3 million, increased RD spending driven by its GLIX1 program, and cash and deposits o...
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility
Aug 28, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases with lead asset GLIX1 in glioblastoma and its approved stem cell mobilization drug APHEXDA for multiple myeloma, continues to advance its pipelin...
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards
Aug 18, 2026
BioLineRx Ltd. reported on August 18, 2026 that it has called its Annual General Meeting of shareholders for September 23, 2026 at its Modi’in headquarters in Israel, with record date set at August 24, 2026 for holders of ordinary shares and...
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion
Jul 8, 2026
On July 8, 2026, BioLineRx and Hemispherian reported new preclinical data from a patient-derived ovarian cancer xenograft model showing strong synergy between GLIX1 and the PARP inhibitor olaparib. In six study arms, a low-dose GLIX1/olaparib comb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.